Bowen Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bowen Cui has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Bing Chen
41 shared publicationsBingshun Wang
41 shared publicationsHai Fang
41 shared publicationsHongming Zhu
41 shared publicationsJunmin Li
41 shared publicationsLi Chen
41 shared publications
Latest Publications
- 11 August 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (10) , 2533-2537
Clinically associated genomic landscape of pediatric non-Down Syndrome acute megakaryoblastic leukemia in Chinese patients
- 11 August 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (10) , 2533-2537
Clinically associated genomic landscape of pediatric non-Down Syndrome acute megakaryoblastic leukemia in Chinese patients
- Open Access
- 7 April 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 23 (2)
Glycolysis Induces Abnormal Transcription Through Histone Lactylation in T-cell Acute Lymphoblastic Leukemia
The Warburg effect, characterized by excessive lactate production, and transcriptional dysregulation are two hallmarks of tumors. However, the precise influence of lactate on epigenetic modifications at a genome-wide level and its impact on gene transcription in tumor cells remain unclear. In this study, we conducted genome-wide profiling of histone H3 lysine 18 lactylation (H3K18la) in T-cell acute lymphoblastic leukemia (T-ALL). We observed elevated lactate and H3K18la levels in T-ALL cells compared to normal T cells, with H3K18la levels positively associated with cell proliferation. Accordingly, we observed a significant shift in genome-wide H3K18la modifications from T cell immunity in normal T cells to leukemogenesis in T-ALL, correlated with altered gene transcription profiles. We showed that H3K18la primarily functions in active transcriptional regulation and observed clusters of H3K18la modifications resembling super-enhancers. Disrupting H3K18la modification revealed both synergistic and divergent changes between H3K18la and histone H3 lysine 27 acetylation (H3K27ac) modifications. Finally, we found that the high transcription of H3K18la target genes, IGFBP2 and IARS, is associated with inferior prognosis of T-ALL. These findings enhance our understanding of how metabolic disruptions contribute to transcription dysregulation through epigenetic changes in T-ALL, underscoring the interplay of histone modifications in maintaining oncogenic epigenetic stability.
- 7 April 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 23 (2)
Open AccessGlycolysis Induces Abnormal Transcription Through Histone Lactylation in T-cell Acute Lymphoblastic Leukemia
The Warburg effect, characterized by excessive lactate production, and transcriptional dysregulation are two hallmarks of tumors. However, the precise influence of lactate on epigenetic modifications at a genome-wide level and its impact on gene transcription in tumor cells remain unclear. In this study, we conducted genome-wide profiling of histone H3 lysine 18 lactylation (H3K18la) in T-cell acute lymphoblastic leukemia (T-ALL). We observed elevated lactate and H3K18la levels in T-ALL cells compared to normal T cells, with H3K18la levels positively associated with cell proliferation. Accordingly, we observed a significant shift in genome-wide H3K18la modifications from T cell immunity in normal T cells to leukemogenesis in T-ALL, correlated with altered gene transcription profiles. We showed that H3K18la primarily functions in active transcriptional regulation and observed clusters of H3K18la modifications resembling super-enhancers. Disrupting H3K18la modification revealed both synergistic and divergent changes between H3K18la and histone H3 lysine 27 acetylation (H3K27ac) modifications. Finally, we found that the high transcription of H3K18la target genes, IGFBP2 and IARS, is associated with inferior prognosis of T-ALL. These findings enhance our understanding of how metabolic disruptions contribute to transcription dysregulation through epigenetic changes in T-ALL, underscoring the interplay of histone modifications in maintaining oncogenic epigenetic stability.
- Open Access
- 25 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Chromatin accessibility landscape of relapsed pediatric B-lineage acute lymphoblastic leukemia
For around half of the pediatric B-lineage acute lymphoblastic leukemia (B-ALL) patients, the molecular mechanism of relapse remains unclear. To fill this gap in knowledge, here we characterize the chromatin accessibility landscape in pediatric relapsed B-ALL. We observe rewired accessible chromatin regions (ACRs) associated with transcription dysregulation in leukemia cells as compared with normal B-cell progenitors. We show that over a quarter of the ACRs in B-ALL are in quiescent regions with high heterogeneity among B-ALLs. We identify subtype-specific and allele-imbalanced chromatin accessibility by integrating multi-omics data. By characterizing the differential ACRs between diagnosis and relapse in B-ALL, we identify alterations in chromatin accessibility during drug treatment. Further analysis of ACRs associated with relapse free survival leads to the identification of a subgroup of B-ALL which show early relapse. These data provide an advanced and integrative portrait of the importance of chromatin accessibility alterations in tumorigenesis and drug responses.
- 25 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Open AccessChromatin accessibility landscape of relapsed pediatric B-lineage acute lymphoblastic leukemia
For around half of the pediatric B-lineage acute lymphoblastic leukemia (B-ALL) patients, the molecular mechanism of relapse remains unclear. To fill this gap in knowledge, here we characterize the chromatin accessibility landscape in pediatric relapsed B-ALL. We observe rewired accessible chromatin regions (ACRs) associated with transcription dysregulation in leukemia cells as compared with normal B-cell progenitors. We show that over a quarter of the ACRs in B-ALL are in quiescent regions with high heterogeneity among B-ALLs. We identify subtype-specific and allele-imbalanced chromatin accessibility by integrating multi-omics data. By characterizing the differential ACRs between diagnosis and relapse in B-ALL, we identify alterations in chromatin accessibility during drug treatment. Further analysis of ACRs associated with relapse free survival leads to the identification of a subgroup of B-ALL which show early relapse. These data provide an advanced and integrative portrait of the importance of chromatin accessibility alterations in tumorigenesis and drug responses.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S2. Summary of somatic mutations in 348 patients with primary APL detected using whole-exome sequencing, whole-genome sequencing, and RNA sequencing. (A) The number of different variant classifications. (B) The number of different variant types. (C) The number of variants per sample. (D) The number of SNVs class. SNVs, single-nucleotide variations; INSs, insertions; DELs, deletions.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S2. Summary of somatic mutations in 348 patients with primary APL detected using whole-exome sequencing, whole-genome sequencing, and RNA sequencing. (A) The number of different variant classifications. (B) The number of different variant types. (C) The number of variants per sample. (D) The number of SNVs class. SNVs, single-nucleotide variations; INSs, insertions; DELs, deletions.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S12 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S12. The agreement between the predicted and the actual EFS of the new score system. The 1000-sample bootstrapped calibration plots at 1-year (A), 2-year (B), and 5-year (C) of the integrated model by using white blood cell count, APL9 score, and NRAS mutations
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S12. The agreement between the predicted and the actual EFS of the new score system. The 1000-sample bootstrapped calibration plots at 1-year (A), 2-year (B), and 5-year (C) of the integrated model by using white blood cell count, APL9 score, and NRAS mutations
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S15 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S15. Kaplan-Meier plots of Combined Sanz groups and ROC plots between the Sanz score and the revised risk score. Kaplan-Meier estimates of OS (A), EFS (B), and DFS (C) when combining the Sanz low- and intermediate-risk into a single category. Comparision of the OS (D), EFS (E), and DFS (F) ROC curves between the Sanz score and the revised model score. P-value is calculated using the log-rank test. OS, overall survival; EFS, event-free survival; DFS, disease-free survival; ROC,receiver operating characteristic.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S15 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S15. Kaplan-Meier plots of Combined Sanz groups and ROC plots between the Sanz score and the revised risk score. Kaplan-Meier estimates of OS (A), EFS (B), and DFS (C) when combining the Sanz low- and intermediate-risk into a single category. Comparision of the OS (D), EFS (E), and DFS (F) ROC curves between the Sanz score and the revised model score. P-value is calculated using the log-rank test. OS, overall survival; EFS, event-free survival; DFS, disease-free survival; ROC,receiver operating characteristic.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S3. Genes newly found in APL and pairwise comparison among Sanz risk groups. (A) Schematic representation of three genes newly found in APL. (B) Genes with significant differences in the pairwise comparison among Sanz risk groups. P-value is calculated using the Fisher's exact test
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S3. Genes newly found in APL and pairwise comparison among Sanz risk groups. (A) Schematic representation of three genes newly found in APL. (B) Genes with significant differences in the pairwise comparison among Sanz risk groups. P-value is calculated using the Fisher's exact test
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S5. Unsupervised hierarchical clustering of the global gene expression profile from 323 patients with APL. Genes and samples are clustered using the ward.D method, and distances are calculated on the basis of the Pearson's correlation coefficient. Columns indicate patients with APL and rows indicate genes.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S5. Unsupervised hierarchical clustering of the global gene expression profile from 323 patients with APL. Genes and samples are clustered using the ward.D method, and distances are calculated on the basis of the Pearson's correlation coefficient. Columns indicate patients with APL and rows indicate genes.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S8 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S8. Spearman's correlation between the gene expression (x axis) and methylation level (y axis) at different regions of GATA1 in patients with APL from the The Cancer Genome Atlas (TCGA) dataset (n = 15). P-values are indicated on each panel. The line shown is a y~x regression line, and the shaded regions are the 95% confidence intervals for the slope of the line.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S8. Spearman's correlation between the gene expression (x axis) and methylation level (y axis) at different regions of GATA1 in patients with APL from the The Cancer Genome Atlas (TCGA) dataset (n = 15). P-values are indicated on each panel. The line shown is a y~x regression line, and the shaded regions are the 95% confidence intervals for the slope of the line.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S1. Kaplan-Meier plot of clinical outcomes in consolidation arms with or without ATO. Kaplan-Meier estimates of overall survival (A), event-free survival (B), and disease-free survival (C) in accordance with the consolidation arms with or without ATO. P-value is calculated using the log-rank test.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Figure S1. Kaplan-Meier plot of clinical outcomes in consolidation arms with or without ATO. Kaplan-Meier estimates of overall survival (A), event-free survival (B), and disease-free survival (C) in accordance with the consolidation arms with or without ATO. P-value is calculated using the log-rank test.